The diseases we work on include:
Clinical trails
Lorem ipsum dolor sit amet, consectetuer adipiscing elit, sed diam nonummy bh euismod tincidunt ut laoreet dolore magna aliquam erat
Global sites
Lorem ipsum dolor sit amet, consectetuer adipiscing elit, sed diam nonummy bh euismod tincidunt ut laoreet dolore magna aliquam erat
Imaging facilities
Lorem ipsum dolor sit amet, consectetuer adipiscing elit, sed diam nonummy bh euismod tincidunt ut laoreet dolore magna aliquam erat
The diseases we work on include:
Early Phase Clinical Development
We have extensive experience in definition and delivery of early-phase clinical development, where rigorous patient safety screening runs hand-in-hand with flexibility around trial design and data analytics.
Late Phase Clinical Development
IXICO’s global network of over 2,000 imaging sites and bespoke TrialTracker platform ensure that large-scale trials can be set up quickly and efficiently to deliver data that is as reliable as it is regulatory compliant.
Post Marketing
IXICO's expertise in data analytics makes us a perfect partner for continued assessment once a drug is licensed. IXICO understands the challenges of extended longitudinal studies, and the importance of monitoring patient safety and drug utilisation for ongoing optimisation of patient pathways.
Early Phase Clinical Development
We have extensive experience in definition and delivery of early-phase clinical development, where rigorous patient safety screening runs hand-in-hand with flexibility around trial design and data analytics.
Late Phase Clinical Development
IXICO’s global network of over 2,000 imaging sites and bespoke TrialTracker platform ensure that large-scale trials can be set up quickly and efficiently to deliver data that is as reliable as it is regulatory compliant.
Post Marketing
IXICO's expertise in data analytics makes us a perfect partner for continued assessment once a drug is licensed. IXICO understands the challenges of extended longitudinal studies, and the importance of monitoring patient safety and drug utilisation for ongoing optimisation of patient pathways.
Meet the team
Charles joined the Board of IXICO in 2013. He is an experienced Director of, and adviser to, public and private companies primarily in the medtech and life science sectors.
He is Non-Executive Chairman of Realm Therapeutics plc, Creo Medical Group plc and 11 Health Technologies Limited and chairs the UK Department of Health Invention for Innovation Funding Panel.
Giulio joined IXICO as Chief Executive Officer in February 2017. He has over 30 years of experience in the life sciences sector and a track record of growing business operations in Europe, the US and Asia. Prior to IXICO, Giulio held global leadership roles at ThermoFisher Scientific and the LGC Ltd, where he transformed the scale of LGC’s Genomics division, completing 3 acquisitions in under 18 months. Giulio was a member of the executive leadership responsible for the successful sale of the LGC Ltd to global investment firm, KKR & Co. Inc.
Susan joined IXICO as Chief Financial Officer in October 2014. She is an experienced Executive Director with previous Board positions including Group Chief Financial Officer of Novacyt SA and Chief Financial Officer of Lab21 Ltd prior to its acquisition by Novacyt. Susan was Chief Financial Officer of BioWisdom until its acquisition by Instem plc and Finance Director of RiboTargets Limited until its acquisition by Vernalis plc.
Lorem ipsum dolor sit amet, consectetuer adipiscing elit, sed diam nonumm.
Lorem ipsum dolor sit amet, consectetuer adipiscing elit, sed diam nonummy bh euismod tincidunt ut laoreet dolore magna aliquam eratLorem ipsum dolor sit amet, consectetuer adipiscing elit, sed diam nonummy bh euismod tincidunt ut laoreet dolore magna aliquam eratLorem ipsum dolor sit amet,
consectetuer adipiscing elit, sed diam nonummy bh euismod tincidunt ut laoreet dolore magna aliquam eratLorem ipsum dolor sit amet, consectetue.Lorem ipsum dolor sit amet, consectetuer adipiscing elit, sed diam nonummy bh euismod tincidunt ut laoreet dolore magna aliquam eratLorem ipsum dolor sit amet, consectetuer adipiscing elit, sed diam nonummy bh euismod tincidunt ut laoreet dolore magna aliquam eratLorem ipsum dolor sit amet, consectetuer adipiscing elit, sed diam nonummy bh euismod tincidunt ut laoreet dolore magna aliquam eratLorem ipsum dolor sit amet, consectetue.Lorem ipsum dolor sit amet, consectetuer adipiscing elit, sed diam nonummy bh euismod tincidunt ut laoreet dolore magna aliquam eratLorem ipsum dolor sit amet, consectetuer adipiscing elit, sed diam nonummy bh euismod tincidunt ut laoreet dolore magna aliquam eratLorem ipsum dolor sit amet, consectetuer adipiscing elit, sed diam nonummy bh euismod tincidunt ut laoreet dolore magna aliquam eratLorem ipsum dolor sit amet, consectetue.
Early Phase Clinical Development
Lorem ipsum dolor sit amet, consectetuer adipiscing elit, sed diam nonummy bh euismod tincidunt ut laoreet dolore magna
aliquam eratLorem ipsum dolor sit amet, consectetuer adipiscing elit, sed diam nonummy bh euismod tincidunt ut laoreet dolore magna aliquam eratLorem ipsum dolor sit amet, consectetuer adipiscing elit, sed diam nonummy bh euismod tincidunt ut laoreet dolore magna aliquam eratLorem ipsum dolor sit amet, consectetue.Lorem ipsum dolor sit amet, consectetuer adipiscing elit, sed diam nonummy Wuismod tincidunt ut laoreet dolore magna aliquam eratLorem ipsum dolor sit amet, consectetuer adipiscing elit, sed diam nonummy bh euismod tincidunt ut laoreet dolore magna aliquam.
Maximise the ability to extract exploritory endpoints
It is often a requirement to explore a number of exploratory endpoints including new and novel data analytics. IXICO continuously adds to and advances the available analysis pipelines, looking at disease-specific regions of interest, indices, and other endpoints. It is important to ensure full validation and rigor around data collection, to enable use and translation into later-phase submission trials.
The ability to extract more reports and endpoints
It is often a requirement to explore a number of exploratory endpoints including new and novel data analytics. IXICO continuously adds to and advances the available analysis pipelines, looking at disease-specific regions of interest, indices, and other endpoints. It is important to ensure full validation and rigor around data collection, to enable use and translation into later-phase submission trials.
Maximise the ability to extract exploritory endpoints
It is often a requirement to explore a number of exploratory endpoints including new and novel data analytics. IXICO continuously adds to and advances the available analysis pipelines, looking at disease-specific regions of interest, indices, and other endpoints. It is important to ensure full validation and rigor around data collection, to enable use and translation into later-phase submission trials.
Maximise the ability to extract exploritory endpoints
It is often a requirement to explore a number of exploratory endpoints including new and novel data analytics. IXICO continuously adds to and advances the available analysis pipelines, looking at disease-specific regions of interest, indices, and other endpoints. It is important to ensure full validation and rigor around data collection, to enable use and translation into later-phase submission trials.
Maximise the ability to extract exploritory endpoints
It is often a requirement to explore a number of exploratory endpoints including new and novel data analytics. IXICO continuously adds to and advances the available analysis pipelines, looking at disease-specific regions of interest, indices, and other endpoints. It is important to ensure full validation and rigor around data collection, to enable use and translation into later-phase submission trials.
Map elements
Lorem ipsum dolor sit amet, consectetuer adipiscing elit, sed diam nonummy bh euismod tincidunt ut laoreet dolore magna aliquam eratLorem ipsum dolor sit amet, consectetuer adipiscing elit, sed diam nonummy bh euismod tincidunt ut laoreet dolore magna aliquam erat
United States of America
Lorem ipsum dolor sit amet, consectetuer adipiscing
Australia
Lorem ipsum dolor sit amet, consectetuer adipiscing
Video Block
Lorem ipsum dolor sit amet, consectetuer adipiscing elit, sed diam nonummy nibh euismod tincidunt ut laoreet dolore magna aliquam erat volutpat. Ut wisi enim ad minim veniam, quis nostrud exerci tation ullamcorper suscipit lobortis nisl ut aliquip ex ea commodo consequat. Duis autem vel eum iriure dolor in hendrerit in vulputate velit esse molestie consequat, vel illum dolore eu feugiat nulla facilisis at vero eros et accumsan et iustLorem ipsum dolor sit amet, consectetuer adipiscing elit, sed diam nonummy nibh euismod tincidunt ut laoreet dolore magna aliquam erat volutpat. Ut wisi enim ad minim veniam.
Quis nostrud exerci tation ullamcorper suscipit lobortis nisl ut aliquip ex ea commodo consequat. Duis autem vel eum iriure
We cannot play this video. The video is embedded from YouTube, your current cookie preferences do not allow the storing of some of the cookies the player will place.
Vimeo Block
Lorem ipsum dolor sit amet, consectetuer adipiscing elit, sed diam nonummy nibh euismod tincidunt ut laoreet dolore magna aliquam erat volutpat. Ut wisi enim ad minim veniam, quis nostrud exerci tation ullamcorper suscipit lobortis nisl ut aliquip ex ea commodo consequat. Duis autem vel eum iriure dolor in hendrerit in vulputate velit esse molestie consequat, vel illum dolore eu feugiat nulla facilisis at vero eros et accumsan et iustLorem ipsum dolor sit amet, consectetuer adipiscing elit, sed diam nonummy nibh euismod tincidunt ut laoreet dolore magna aliquam erat volutpat. Ut wisi enim ad minim veniam.
Quis nostrud exerci tation ullamcorper suscipit lobortis nisl ut aliquip ex ea commodo consequat. Duis autem vel eum iriure
We cannot play this video. The video is embedded from YouTube, your current cookie preferences do not allow the storing of some of the cookies the player will place.
Assessa®
Clinical decision support for patient selection and post-marketing surveillance
We partner with biopharma companies to improve clinical trial patient selection and provide clinical decision support services to improve the safety and efficacy of their therapeutics.
Assessa is a secure online digital platform to enable the remote transfer of clinical and imaging data to provide central expert and automated review and analysis. Referring clinicians then receive actionable information to inform treatment decisions at the point-of-care.
Assessa®
Clinical decision support for patient selection and post-marketing surveillance
We partner with biopharma companies to improve clinical trial patient selection and provide clinical decision support services to improve the safety and efficacy of their therapeutics.
Assessa is a secure online digital platform to enable the remote transfer of clinical and imaging data to provide central expert and automated review and analysis. Referring clinicians then receive actionable information to inform treatment decisions at the point-of-care.
CEO Videos
CEO Videos
CEO Videos
CEO Videos
Science with scale
We work with biopharma to support drug development and clinical decision support by advising on novel imaging and digital biomarkers with expert data analysis. Our unique end-to-end digital platform encompasses the entire drug development lifecycle from phase I to IV, including post marketing surveillance.
Our platform is a scalable and secure infrastructure for the standardisation, capture, analysis and reporting of regulatory compliant clinical data. Our analysis and reporting solutions are chosen by biopharma to better select patients for clinical trials and assess the safety and efficacy of new drugs in development and those on the market today.
With our expertise, our biopharma clients make rapid, better informed, clinically meaningful decisions, more cost effectively.
Science with scale
We work with biopharma to support drug development and clinical decision support by advising on novel imaging and digital biomarkers with expert data analysis. Our unique end-to-end digital platform encompasses the entire drug development lifecycle from phase I to IV, including post marketing surveillance.
Our platform is a scalable and secure infrastructure for the standardisation, capture, analysis and reporting of regulatory compliant clinical data. Our analysis and reporting solutions are chosen by biopharma to better select patients for clinical trials and assess the safety and efficacy of new drugs in development and those on the market today.
With our expertise, our biopharma clients make rapid, better informed, clinically meaningful decisions, more cost effectively.
Science with scale
We work with biopharma to support drug development and clinical decision support by advising on novel imaging and digital biomarkers with expert data analysis. Our unique end-to-end digital platform encompasses the entire drug development lifecycle from phase I to IV, including post marketing surveillance.
Our platform is a scalable and secure infrastructure for the standardisation, capture, analysis and reporting of regulatory compliant clinical data. Our analysis and reporting solutions are chosen by biopharma to better select patients for clinical trials and assess the safety and efficacy of new drugs in development and those on the market today.
With our expertise, our biopharma clients make rapid, better informed, clinically meaningful decisions, more cost effectively.
Infographic title
Phase 1 Step 1
Phase 1 Step 2
Lorem ipsum dolor sit amet, consectetuer adipiscing elit, sed diam nonummy nibh euismod tincidunt ut laoreet dolore magnLorem ipsum dolor sit amet, consectetuer adipiscing elit, sed diam nonummy nibh euismod tincidunt ut laoreet dolore magna a
Phase 1 Step 3
Lorem ipsum dolor sit amet, consectetuer adipiscing elit, sed diam nonummy nibh euismod tincidunt ut